» Articles » PMID: 37067466

Using Cluster Theory to Calculate the Experimental Structure Factors of Antibody Solutions

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2023 Apr 17
PMID 37067466
Authors
Affiliations
Soon will be listed here.
Abstract

Monoclonal antibody solutions are set to become a major therapeutic tool in the years to come, capable of targeting various diseases by clever design of their antigen binding site. However, the formulation of stable solutions suitable for patient self-administration typically presents challenges, as a result of the increase in viscosity that often occurs at high concentrations. Here, we establish a link between the microscopic molecular details and the resulting properties of an antibody solution through the characterization of clusters, which arise in the presence of self-associating antibodies. In particular, we find that experimental small-angle X-ray scattering data can be interpreted by means of analytical models previously exploited for the study of polymeric and colloidal objects, based on the presence of such clusters. The latter are determined by theoretical calculations and supported by computer simulations of a coarse-grained minimal model, in which antibodies are treated as Y-shaped colloidal molecules and attractive domains are designed as patches. Using the theoretically predicted cluster size distributions, we are able to describe the experimental structure factors over a wide range of concentration and salt conditions. We thus provide microscopic evidence for the well-established fact that the concentration-dependent increase in viscosity is originated by the presence of clusters. Our findings bring new insights on the self-assembly of monoclonal antibodies, which can be exploited for guiding the formulation of stable and effective antibody solutions.

Citing Articles

Reconciling predicted and measured viscosity parameters in high concentration therapeutic antibody solutions.

Armstrong G, Roche A, Lewis W, Rattray Z MAbs. 2024; 16(1):2438172.

PMID: 39663541 PMC: 11790245. DOI: 10.1080/19420862.2024.2438172.


Combining Scattering Experiments and Colloid Theory to Characterize Charge Effects in Concentrated Antibody Solutions.

Gulotta A, Polimeni M, Lenton S, Starr C, Stradner A, Zaccarelli E Mol Pharm. 2024; 21(5):2250-2271.

PMID: 38661388 PMC: 11080060. DOI: 10.1021/acs.molpharmaceut.3c01023.


A multi-scale numerical approach to study monoclonal antibodies in solution.

Polimeni M, Zaccarelli E, Gulotta A, Lund M, Stradner A, Schurtenberger P APL Bioeng. 2024; 8(1):016111.

PMID: 38425712 PMC: 10902793. DOI: 10.1063/5.0186642.


Poly(glutamic acid)-Based Viscosity Reducers for Concentrated Formulations of a Monoclonal IgG Antibody.

Lapenna A, Dagallier C, Huille S, Tribet C Mol Pharm. 2024; 21(2):982-991.

PMID: 38240032 PMC: 10849046. DOI: 10.1021/acs.molpharmaceut.3c01159.

References
1.
Calero-Rubio C, Saluja A, Roberts C . Coarse-Grained Antibody Models for "Weak" Protein-Protein Interactions from Low to High Concentrations. J Phys Chem B. 2016; 120(27):6592-605. DOI: 10.1021/acs.jpcb.6b04907. View

2.
Roberts C . Protein aggregation and its impact on product quality. Curr Opin Biotechnol. 2014; 30:211-7. PMC: 4266928. DOI: 10.1016/j.copbio.2014.08.001. View

3.
Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H . Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020; 27(1):1. PMC: 6939334. DOI: 10.1186/s12929-019-0592-z. View

4.
Bittner B, Richter W, Schmidt J . Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs. 2018; 32(5):425-440. PMC: 6182494. DOI: 10.1007/s40259-018-0295-0. View

5.
Skar-Gislinge N, Ronti M, Garting T, Rischel C, Schurtenberger P, Zaccarelli E . A Colloid Approach to Self-Assembling Antibodies. Mol Pharm. 2019; 16(6):2394-2404. DOI: 10.1021/acs.molpharmaceut.9b00019. View